ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
23 announcements
Pfizer Limited reported unaudited financial results for the quarter ended September 30, 2026. The company recorded a net profit of Rs. 313.25 Crore on total income of Rs. 774.19 Crore.
Pfizer Limited has scheduled a board meeting for 3 November 2026 to consider unaudited standalone half-yearly results for the period ended September 2026. The trading window closes from 30 September 2026 until 5 November 2026.
Pfizer Ltd has filed its quarterly shareholding pattern as per SEBI regulations. This is a routine compliance disclosure.
Pfizer Limited received a penalty order of Rs. 1.26 Crore from the Income Tax department regarding transfer pricing. The company plans to appeal the order and expects no material financial impact.
Pfizer Limited announced the resignation of Mr. Sharad Goswami, Senior Director – Policy & Public Affairs, effective from the close of business on September 25, 2026.
Pfizer Board approved discontinuation of Minipress XL effective September 7, 2026. The company will receive ₹131.38 Crore lump-sum payment from Pfizer Inc., USA.
Pfizer Limited held its 75th Annual General Meeting on July 28, 2026. The meeting covered the adoption of financial statements, dividend declaration, and auditor remuneration ratification.
Pfizer Ltd reported revenue from operations of ₹653.2 Cr (+8.3% YoY) and net profit of ₹204.5 Cr (+6.6% YoY) for Q1 FY27.
Mr. Amit Agarwal has resigned as the Executive Director – Finance & Chief Financial Officer and Director of Pfizer Limited, effective October 8, 2026.
Pfizer Limited has scheduled a board meeting for July 28, 2026, to consider and approve the unaudited standalone financial results for the quarter ended June 2026.
Pfizer clarified that Premarin Vaginal Cream's temporary discontinuation due to supply constraints has no material impact. The product contributes less than 1% of total revenue.
Pfizer Limited will hold its 75th AGM on July 28, 2026, via video conferencing. The agenda includes adoption of financial statements and declaration of a Rs.75/- per share dividend.
Pfizer Ltd filed its Annual Report for FY 2025-26. The report highlights ₹2,520 Cr revenue and recommends a ₹75/share dividend.
Pfizer Limited submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The report confirms overall regulatory compliance with SEBI and exchange listing requirements.
Pfizer Ltd reported revenue from operations of ₹629.2 Cr (+6.3% YoY) and net profit of ₹199.8 Cr (-39.6% YoY) for Q4 FY26.
Pfizer Limited recommended a final dividend of ₹7.5 per share for fiscal 2026. The record date is set for July 17, 2026, with payments starting August 4.
Pfizer Limited scheduled its 75th Annual General Meeting for July 28, 2026 via video conference. Key resolutions include dividend declaration and financial statement adoption.
Pfizer Limited reported a total income of ₹2707.6 Crore for FY 2025-26. The Board also recommended a final dividend of ₹75 per equity share.
Pfizer Limited has scheduled a Board Meeting for May 12, 2026, to consider and approve financial results for the quarter and year ended March 31, 2026. The board will also consider a dividend recommendation. The company's trading window remains closed until May 14, 2026.
Pfizer Limited has scheduled a board meeting for May 12, 2026. The board will consider and approve audited standalone financial results for the year ended March 31, 2026, and recommend a final dividend. The trading window remains closed until May 14, 2026.
Pfizer Limited has scheduled a board meeting on May 12, 2026, to consider and approve audited standalone financial results for the year ended March 31, 2026. The board will also recommend a final dividend for the financial year 2025-26. The trading window remains closed until May 14, 2026.
Pfizer Ltd received an Income-tax Assessment Order and a tax demand of ₹85.74 Crore for FY 2022-23 due to alleged under-reporting of income. The company is also facing penalty proceedings. Pfizer believes it has strong grounds on merits and does not expect a material impact on its financial position at this stage.
Pfizer Limited clarified a technical error in its XBRL submission for the quarter ended September 30, 2025. Following National Stock Exchange guidance, the company re-filed the Integrated Filing - Financials, correcting the 'Reporting Quarter' selection from 'Half Year' to 'Second quarter'. The revised filing is now correctly reflected on the NSE website.